0000950170-22-010201.txt : 20220517 0000950170-22-010201.hdr.sgml : 20220517 20220517170156 ACCESSION NUMBER: 0000950170-22-010201 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220512 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220517 DATE AS OF CHANGE: 20220517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDNAX, INC. CENTRAL INDEX KEY: 0000893949 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 263667538 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12111 FILM NUMBER: 22935553 BUSINESS ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 BUSINESS PHONE: 9543840175 MAIL ADDRESS: STREET 1: 1301 CONCORD TERRACE CITY: SUNRISE STATE: FL ZIP: 33323 FORMER COMPANY: FORMER CONFORMED NAME: PEDIATRIX MEDICAL GROUP INC DATE OF NAME CHANGE: 19950801 8-K 1 md-20220512.htm 8-K 8-K
0000893949false00008939492022-05-122022-05-12

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2022

 

 

Mednax, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Florida

001-12111

26-3667538

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1301 Concord Terrace

 

Sunrise, Florida

 

33323

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 384-0175

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $.01 per share

 

MD

 

The New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 12, 2022, Mednax, Inc., a Florida corporation (the “Company”), appointed James D. Swift, M.D. as an Executive Vice President and the Company’s Chief Operating Officer. Dr. Swift joined the Company in September 2009 and most recently served as the Company’s Executive Vice President and Chief Development Officer. Dr. Swift received his medical degree from the University of Health Sciences/The Chicago Medical School and is board certified in pediatrics.
 

 

There are no arrangements or understandings between Dr. Swift and any other person pursuant to which he was appointed as Chief Operating Officer of the Company and no family relationships between Dr. Swift and any director or executive officer of the Company. Other than as described in this Current Report on Form 8-K, since the beginning of the Company’s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which Dr. Swift had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On May 12, 2022, the Company held its 2022 Annual Shareholders’ Meeting (the “Annual Meeting”). Of the 87,185,960 shares of common stock outstanding and entitled to vote, 81,415,617 shares were represented, constituting a quorum. The final results for each of the matters submitted to a vote of the Company’s shareholders at the Annual Meeting are as follows:

 

Proposal 1: All of the nominees for the Company’s Board of Directors were elected to serve until the Company’s 2023 Annual Shareholders’ Meeting or until their respective successors are elected and qualified, by the votes set forth in the table below:

 

Name

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

Laura A. Linynsky

 

 

79,610,598

 

 

 

269,397

 

 

 

44,907

 

 

 

1,490,715

 

Thomas A. McEachin

 

 

77,319,861

 

 

 

2,559,102

 

 

 

45,939

 

 

 

1,490,715

 

Roger J. Medel, M.D.

 

 

79,208,485

 

 

 

691,198

 

 

 

25,219

 

 

 

1,490,715

 

Mark S. Ordan

 

 

76,784,354

 

 

 

3,094,598

 

 

 

45,950

 

 

 

1,490,715

 

Michael A. Rucker

 

 

79,340,219

 

 

 

538,830

 

 

 

45,853

 

 

 

1,490,715

 

Guy P. Sansone

 

 

79,293,875

 

 

 

585,173

 

 

 

45,854

 

 

 

1,490,715

 

John M. Starcher, Jr.

 

 

70,763,543

 

 

 

9,114,284

 

 

 

47,075

 

 

 

1,490,715

 

Shirley A. Weis

 

 

70,040,888

 

 

 

9,358,513

 

 

 

525,501

 

 

 

1,490,715

 

 

 

Proposal 2: The appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2022 fiscal year was ratified by the Company’s shareholders, by the votes set forth in the table below:

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

 

78,286,794

 

 

 

3,104,901

 

 

 

23,922

 

 

 

0

 

 

 

Proposal 3: The Company’s shareholders advised against the compensation of the Company’s named executive officers for the 2021 fiscal year, by the votes set forth in the table below:

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

 

34,566,404

 

 

 

45,167,188

 

 

 

191,310

 

 

 

1,490,715

 

 

 

The Company regularly makes efforts to engage with its shareholders and intends to continue to conduct additional outreach to its shareholders in the coming months regarding the outcome of the shareholder advisory vote on compensation of the Company’s named executive officers for the 2021 fiscal year.

 

Proposal 4: The Company’s shareholders approved the Second Amended and Restated Articles of Incorporation by the votes set forth in the table below:

 

For

 

 

Against

 

 

Abstained

 

 

Broker
Non-Vote

 

 

79,850,606

 

 

 

26,115

 

 

 

48,181

 

 

 

1,490,715

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

Mednax, Inc.

 

 

 

 

Date:

May 17, 2022

By:

/s/ C. Marc Richards

 

 

 

C. Marc Richards

Chief Financial Officer
 

 

 EX-101.SCH 2 md-20220512.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 md-20220512_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Information, Former Legal or Registered Name Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 md-20220512_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document And Entity Information
May 12, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 12, 2022
Entity Registrant Name Mednax, Inc.
Entity Central Index Key 0000893949
Entity Emerging Growth Company false
Entity File Number 001-12111
Entity Incorporation, State or Country Code FL
Entity Tax Identification Number 26-3667538
Entity Address, Address Line One 1301 Concord Terrace
Entity Address, City or Town Sunrise
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33323
City Area Code 954
Local Phone Number 384-0175
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.01 per share
Trading Symbol MD
Security Exchange Name NYSE
XML 6 md-20220512_htm.xml IDEA: XBRL DOCUMENT 0000893949 2022-05-12 2022-05-12 0000893949 false 8-K 2022-05-12 Mednax, Inc. FL 001-12111 26-3667538 1301 Concord Terrace Sunrise FL 33323 954 384-0175 N/A false false false false Common Stock, par value $.01 per share MD NYSE false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G7&BN"^)]NK+NY *W3"W\RQ+50/>I"MJ(-.)_#1EZA$VY8<1(86> MY4)88TS<;_3\1C0>09:'[L#TA(XA+@W#"CTN*+N@U6/@24DM0H#E>QV3N7TR@ZN M6>1>9!CG*(.XLH/P4:V%&@/8-SF0!)?DJG547>EYIM[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E% M9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ ,XBQ5&60>9(9 0 SP, !, !;0V]N M=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z3 M9UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A M.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G 8ED\C<+, M:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5C ME>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68* MR,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/ M^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " SB+%4!T%- M8H$ "Q $ @ $ 9&]C4')O<',O87!P+GAM;%!+ M 0(4 Q0 ( #.(L50QN_OP[@ "L" 1 " :\ !D M;V-0&UL4$L! A0#% M @ ,XBQ5 U[(N]3! Z! !@ ("!#0@ 'AL+W=O&UL4$L! A0#% @ ,XBQ M5)>*NQS $P( L ( !<@\ %]R96QS+RYR96QS4$L! M A0#% @ ,XBQ5#JJHN= 0 / ( \ ( !6Q 'AL M+W=O7!E&UL4$L%!@ ) D /@( /<3 $! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports md-20220512.htm md-20220512.xsd md-20220512_lab.xml md-20220512_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "md-20220512.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "md-20220512.htm" ] }, "labelLink": { "local": [ "md-20220512_lab.xml" ] }, "presentationLink": { "local": [ "md-20220512_pre.xml" ] }, "schema": { "local": [ "md-20220512.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "md", "nsuri": "http://www.mednax.com/20220512", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "md-20220512.htm", "contextRef": "C_ab9e73dc-cf44-4582-b908-421837da5e74", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "md-20220512.htm", "contextRef": "C_ab9e73dc-cf44-4582-b908-421837da5e74", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.mednax.com/20220512/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0000950170-22-010201-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-22-010201-xbrl.zip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�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